Advertisement

Prostate Cancer

  • Siavash Jabbari
  • Eric K. Hansen
  • Mack RoachIII
Chapter

Abstract

Prostate cancer is the #1 noncutaneous cancer in men (∼186,320 estimated cases in the US in 2008), and is the #2 cause of cancer mortality (∼28,660 deaths in 2008) after lung cancer (∼90,810 deaths). The median age at diagnosis is 70, but with increased screening, more younger men are being diagnosed. Due to its long natural history, many men may not benefit from treatment if their life expectancy is short (<5–10 years) and if they have early-stage, low-grade disease. Prostate gland consists of the peripheral zone (70% of glandular prostate and site of nearly all cancers), the central zone (25% of the glandular prostate), the transition zone (surrounding the urethra and the site of BPH), and the anterior fibromuscular stroma.

Keywords

Radical Prostatectomy Gleason Score American Urology Association Electronic Portal Imaging Device Glandular Prostate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

References

  1. Aizer AA, Yu JB, McKeon AM, et al. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009;75(5):1344-1349.Google Scholar
  2. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72(4):980-988.PubMedCrossRefGoogle Scholar
  3. Bayley AJ, Catton CN, Haycocks T, et al. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother Oncol 2004;70:37-44.PubMedCrossRefGoogle Scholar
  4. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57:263-267.PubMedCrossRefGoogle Scholar
  5. Beyer DC. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 2003;13:158-165.PubMedCrossRefGoogle Scholar
  6. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100(16):1144-1154.PubMedCrossRefGoogle Scholar
  7. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 12 2005;352(19):1977-1984.CrossRefGoogle Scholar
  8. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984.PubMedCrossRefGoogle Scholar
  9. Black PC, Basen-Engquist K, Wang X, et al. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 2007;100(1):63-69.PubMedCrossRefGoogle Scholar
  10. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-106.PubMedCrossRefGoogle Scholar
  11. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. NEJM 2009;360:2516-2527.PubMedCrossRefGoogle Scholar
  12. Chao KS, Lin M. Lymphangiogram-assisted lymph node target delineation for patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:1147-1152.PubMedCrossRefGoogle Scholar
  13. Cheung MR, Tucker SL, Dong L, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007;67(4):1059-1065.PubMedCrossRefGoogle Scholar
  14. Cheung R, Kamat AM, de Crevoisier R, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63(1):134-140.PubMedCrossRefGoogle Scholar
  15. Chun FK, Briganti A, Shariat SF, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 2006;98(2):329-334.PubMedCrossRefGoogle Scholar
  16. Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Urology 1999;54(3):495-502.PubMedCrossRefGoogle Scholar
  17. Crook J, Ludgate C, Malone S, et al. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73(2):327-333.PubMedCrossRefGoogle Scholar
  18. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004a;351:125-135.PubMedCrossRefGoogle Scholar
  19. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004b;292:821-827.PubMedCrossRefGoogle Scholar
  20. D’Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447.PubMedCrossRefGoogle Scholar
  21. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.PubMedCrossRefGoogle Scholar
  22. D’Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008;26(18):2979-2983.PubMedCrossRefGoogle Scholar
  23. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299(3):289-295.PubMedCrossRefGoogle Scholar
  24. Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009;55(5):1003-1011.Google Scholar
  25. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8(6):475-487.PubMedCrossRefGoogle Scholar
  26. Eade TN, Horwitz EM, et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008;71(2):338-345.PubMedCrossRefGoogle Scholar
  27. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008;54(4):816-823.PubMedCrossRefGoogle Scholar
  28. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-439.PubMedCrossRefGoogle Scholar
  29. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1048-1055.PubMedCrossRefGoogle Scholar
  30. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:1098-1104PubMedCrossRefGoogle Scholar
  31. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235-246.Google Scholar
  32. Jabbari S, Weinberg VK, Shinohara K, et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 76(1):36-42.Google Scholar
  33. Jacob R, Hanlon AL, Horwitz EM, et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005;61(3):695-701PubMedCrossRefGoogle Scholar
  34. King CR, Presti JC, Jr., Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004;59(2):341-347.PubMedCrossRefGoogle Scholar
  35. Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004;172:S48-50; discussion S50-S41.Google Scholar
  36. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74.PubMedCrossRefGoogle Scholar
  37. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.PubMedCrossRefGoogle Scholar
  38. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68(5):1424-1430.PubMedCrossRefGoogle Scholar
  39. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002;167(1):117-122.PubMedCrossRefGoogle Scholar
  40. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37(2):247-252.PubMedCrossRefGoogle Scholar
  41. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008;70(2):437-441.PubMedCrossRefGoogle Scholar
  42. Lawton CA, DeSilvio M, Roach M III, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69(3):646-655.PubMedCrossRefGoogle Scholar
  43. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;74(2):383-387.PubMedCrossRefGoogle Scholar
  44. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300(2):173-181.PubMedCrossRefGoogle Scholar
  45. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-1788.PubMedCrossRefGoogle Scholar
  46. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-479.PubMedCrossRefGoogle Scholar
  47. Miller J, Smith A, Kouba E, Wallen E, Pruthi RS. Prospective evaluation of short-term impact and recovery of health related quality of life in men undergoing robotic assisted laparoscopic radical prostatectomy versus open radical prostatectomy. J Urol 2007;178(3 Pt 1):854-858; discussion 859.PubMedCrossRefGoogle Scholar
  48. Ng LG, Yip S, Tan PH, Yuen J, Lau W, Cheng C. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. Asian J Surg 2002;25(3):238-243.PubMedCrossRefGoogle Scholar
  49. Pagliarulo V, Hawes D, Brands FH, et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006;24(18):2735-2742.PubMedCrossRefGoogle Scholar
  50. Pan CC, Kim KY, Taylor JM, et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2002;53(5):139-1145PubMedCrossRefGoogle Scholar
  51. Patel AA, Chen MH, Renshaw AA, D’Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007;298(13):1533-1538.PubMedCrossRefGoogle Scholar
  52. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990-1996.PubMedCrossRefGoogle Scholar
  53. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005;173(5):1701-1705.PubMedCrossRefGoogle Scholar
  54. Penson DF. An update on randomized clinical trials in localized and locoregional prostate cancer. Urol Oncol 2005;23(4):280-288.PubMedCrossRefGoogle Scholar
  55. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-1021.PubMedGoogle Scholar
  56. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.PubMedCrossRefGoogle Scholar
  57. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64(2):518-526.PubMedCrossRefGoogle Scholar
  58. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18: 3904-3911.PubMedGoogle Scholar
  59. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25(34):5366-5373.PubMedCrossRefGoogle Scholar
  60. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.PubMedCrossRefGoogle Scholar
  61. Roach M III, DeSilvio M, Valicenti R, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66(3):647-653.PubMedCrossRefGoogle Scholar
  62. Roach M III. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol 1 2008;26(22):3816-3817; author reply 3817-3818.CrossRefGoogle Scholar
  63. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-1068.PubMedCrossRefGoogle Scholar
  64. Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 2009;73(3):672-678.PubMedCrossRefGoogle Scholar
  65. Sandler HM, DeSilvio M, Pienta K, et al. Preliminary analysis of RTOG 9902: increased toxicity observed with the use of adjuvant chemotherapy. Proceedings of the American Society for Therapeutic Radiology and Oncology 47th Annual Meeting. 10 January 2005, Int J Radiat Oncol Biol Phys 2005;63(Suppl 1):S123.CrossRefGoogle Scholar
  66. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-1199.PubMedCrossRefGoogle Scholar
  67. Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998;42(5):1055-1062PubMedCrossRefGoogle Scholar
  68. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005;63:1262-1269.PubMedCrossRefGoogle Scholar
  69. Sidhom MA, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008;88(1):10-19.PubMedCrossRefGoogle Scholar
  70. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007;69(1):54-61.PubMedCrossRefGoogle Scholar
  71. Stephenson AJ, Scardino PT, et al. Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-2041.PubMedCrossRefGoogle Scholar
  72. Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76(2):355-360.Google Scholar
  73. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-1876.PubMedCrossRefGoogle Scholar
  74. Swanson GP, Riggs MW, Herman M. Long-term outcome for lymph node-positive prostate cancer. Prostate Cancer Prostatic Dis 2008;11(2):198-202.PubMedCrossRefGoogle Scholar
  75. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.PubMedCrossRefGoogle Scholar
  76. Taylor A, Rockall AG, Rezneck RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:1604-1612.PubMedCrossRefGoogle Scholar
  77. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.PubMedCrossRefGoogle Scholar
  78. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181(3):956-962.PubMedCrossRefGoogle Scholar
  79. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006;175(2):547-551.PubMedCrossRefGoogle Scholar
  80. Trock BJ, Han M, et al. Prostate cancer–specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760-2769PubMedCrossRefGoogle Scholar
  81. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 2006;107(10):2392-2400.PubMedCrossRefGoogle Scholar
  82. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25(27):4178-4186.PubMedCrossRefGoogle Scholar
  83. Vickers AJ, Savage C, O’Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27(3): 398-403.PubMedCrossRefGoogle Scholar
  84. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373(9660):301-308.PubMedCrossRefGoogle Scholar
  85. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27(18):2924-2930.PubMedCrossRefGoogle Scholar
  86. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006;296(22):2683-2693.PubMedCrossRefGoogle Scholar
  87. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006;66(4):1072-1083.PubMedCrossRefGoogle Scholar
  88. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 2001;58:233-239.PubMedCrossRefGoogle Scholar
  89. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67(2):327-333.PubMedCrossRefGoogle Scholar
  90. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007;67(1):65-70.PubMedCrossRefGoogle Scholar
  91. Zietman AL, DeSilvio M, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005;294:1233-1239.PubMedCrossRefGoogle Scholar
  92. Zietman AL. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 2008;299(8):898-899.PubMedCrossRefGoogle Scholar

Further Readings

  1. Andriole GL, Grubb RL 3rd, Buys SS, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med. 2009;360(13):1310-1319.Google Scholar
  2. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:1798-1803.Google Scholar
  3. Chung T, Speight J, Roach M 3rd. Intermediate and high-risk prostate cancer. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 1483-1502.Google Scholar
  4. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:15-23.Google Scholar
  5. Bolla M, Van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC 22911). Lancet 2005;366:572-578.Google Scholar
  6. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 13-19 2005;366(9485):572-578.Google Scholar
  7. D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25(17):2420-2425.Google Scholar
  8. D’Amico AV, Keshaviah A, Manola J, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:581-587.Google Scholar
  9. D’Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004c;22:3726-3732.Google Scholar
  10. D’Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-1172.Google Scholar
  11. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-850.Google Scholar
  12. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009;27(1):92-99.Google Scholar
  13. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.Google Scholar
  14. Gottschalk AR, Roach M 3rd. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer 2004;90:950-954.Google Scholar
  15. Greene FL. American Joint Committee on Cancer. American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.Google Scholar
  16. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40.Google Scholar
  17. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 2002;59:560-565.Google Scholar
  18. Hanks GE, Lu J, Machtay M, et al. RTOG protocol 92-02: a phase III trial of the use of long term androgen supression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000;48(3 Suppl 1):112.Google Scholar
  19. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally-advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-3978.Google Scholar
  20. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-789.Google Scholar
  21. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.Google Scholar
  22. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-3650.Google Scholar
  23. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003;21:4568-4571.Google Scholar
  24. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 2001;166:1311-1315.Google Scholar
  25. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57:915-928.Google Scholar
  26. Kuban A, Potters L, Lawton C, et al. Prostate cancer. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 1st ed. Philadelphia: Churchill Livingstone; 2007. pp. 1165-1236.Google Scholar
  27. Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:635-644.Google Scholar
  28. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004;171:1137-1140.Google Scholar
  29. Lawton CA, Winter K, Byhardt R, et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1997;38:931-939.Google Scholar
  30. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage d1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31. J Clin Oncol 2005;23:800-807.Google Scholar
  31. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-946.Google Scholar
  32. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61-69.Google Scholar
  33. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf Accessed on January 19, 2005.
  34. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-848.Google Scholar
  35. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351: 1513-1520.Google Scholar
  36. Pickett B, Kurhanewicz J, Coakley F, et al. Efficacy of external beam radiotherapy compared to permanent prostate implant in treating low risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and PSA. Int J Radiat Oncol Biol Phys 2004;60(1 Suppl 1):S185-S186.Google Scholar
  37. Pickett B, Kurhanewicz J, Coakley F, et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:1047-1055.Google Scholar
  38. Pickett B, Ten Haken RK, Kurhanewicz J, et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004;59:665-673.Google Scholar
  39. Pollack A. The prostate. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. pp. 629-680.Google Scholar
  40. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-3705.Google Scholar
  41. Roach III M, Wallner K. Cancer of the Prostate. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 959-1030.Google Scholar
  42. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-1911.Google Scholar
  43. Roach M 3rd. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 2003;170:S35-S40; discussion S40-S31.Google Scholar
  44. Roach M 3rd. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol 2007;25 (33):5325-5326; author reply 5326.Google Scholar
  45. Roach M, 3rd, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617-627.Google Scholar
  46. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000;47:609-615.Google Scholar
  47. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med. 2009;360(13):1320-1328.Google Scholar
  48. Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008;18(3):279-296.Google Scholar
  49. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-1332.Google Scholar
  50. Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003;56:448-453.Google Scholar
  51. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-642.Google Scholar
  52. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-952.Google Scholar
  53. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-943.Google Scholar
  54. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.Google Scholar
  55. Valicenti RK, Gomella LG, Perez CA. Radiation therapy after radical prostatectomy: a review of the issues and options. Semin Radiat Oncol 2003;13:130-140.Google Scholar
  56. Zelefsky MJ, Valicenti RK, Hunt M et al. Low-risk prostate cancer. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 1439-1482.Google Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Siavash Jabbari
    • 1
  • Eric K. Hansen
    • 2
  • Mack RoachIII
    • 3
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Radiation Oncology, The Oregon ClinicProvidence St. Vincent Medical CenterPortlandUS
  3. 3.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations